Literature DB >> 2685718

Modern management of otitis media.

C D Bluestone1.   

Abstract

In summary, infants and children who have acute otitis media should receive antimicrobial therapy. Amoxicillin is the standard of therapy for infants and children with acute otitis media, because it is safe and effective for most of the causative bacterial pathogens. Amoxicillin has also been shown to be effective for treatment of selected children with otitis media with effusion ("secretory" otitis media) and is the recommended prophylactic antimicrobial agent for prevention of frequently recurrent acute otitis media. During the past decade, however, an increasing rate of bacteria that are resistant to amoxicillin has occurred, primarily beta-lactamase-producing H. influenzae and B. catarrhalis. Because of the emergence of these bacteria, other antimicrobial agents, both old and new, have been advocated for treatment and prevention of otitis media; amoxicillin-clavulanate, cefuroxime axetil, and cefixime are the newer agents. These agents are indicated for selected infants and children; however, for most patients, amoxicillin remains a safe and relatively inexpensive effective drug. The common surgical procedures, such as myringotomy with tympanostomy tube insertion, and adenoidectomy with myringotomy with or without tympanostomy tube insertion, have now been shown to be effective for patients who have recurrent acute otitis media and chronic otitis media with effusion. The decision for or against these procedures should not only include consultation with an otolaryngologist but should also involve the parents and the child, if old enough. The risks, costs, and benefits of nonsurgical and surgical management should be discussed with all parties concerned.

Entities:  

Mesh:

Year:  1989        PMID: 2685718     DOI: 10.1016/s0031-3955(16)36794-3

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  12 in total

1.  Otolaryngologists' perceptions of the indications for tympanostomy tube insertion in children.

Authors:  W J McIsaac; P C Coyte; R Croxford; C V Asche; J Friedberg; W Feldman
Journal:  CMAJ       Date:  2000-05-02       Impact factor: 8.262

2.  Cefixime vs amoxicillin in the treatment of acute otitis media in infants and children.

Authors:  N Principi; P Marchisio
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Therapy of acute otitis media. Clinical and economic aspects.

Authors:  R Sagraves; W Maish
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

4.  Acute otitis media in children. Role of antibiotic therapy.

Authors:  T Lehnert
Journal:  Can Fam Physician       Date:  1993-10       Impact factor: 3.275

5.  Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2.

Authors:  Thuan Tong Tan; Jens Jørgen Christensen; Morten Hanefeld Dziegiel; Arne Forsgren; Kristian Riesbeck
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

6.  The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.

Authors:  L E Myers; Y P Yang; R P Du; Q Wang; R E Harkness; A B Schryvers; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Systemic inflammatory responses in children with acute otitis media due to Streptococcus pneumoniae and the impact of treatment with clarithromycin.

Authors:  Gunter Scharer; Frank Zaldivar; Guillermo Gonzalez; Ofelia Vargas-Shiraishi; Jasjit Singh; Antonio Arrieta
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 8.  Practical considerations when treating children with antimicrobials in the outpatient setting.

Authors:  L N Werk; H Bauchner
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

9.  Otitis media. How are First Nations children affected?

Authors:  M Thomson
Journal:  Can Fam Physician       Date:  1994-11       Impact factor: 3.275

10.  Cloning and expression of the Moraxella catarrhalis lactoferrin receptor genes.

Authors:  R P Du; Q Wang; Y P Yang; A B Schryvers; P Chong; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.